Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CervoMed Inc. (NASDAQ: CRVO) SEC filings, offering a detailed view of how the clinical-stage biotechnology company reports its operations, financial condition, and development plans for neflamapimod and related programs. As a NASDAQ Capital Market issuer, CervoMed files current reports on Form 8-K, annual reports on Form 10-K, and other documents that outline its progress in dementia with Lewy bodies (DLB) and other age-related brain disorders.
In recent Form 8-K filings, CervoMed has furnished press releases covering quarterly financial results, new clinical data from the Phase 2b RewinD-LB trial, and written feedback from the U.S. Food and Drug Administration on the design of its planned Phase 3 trial in DLB. These filings describe how the company plans to use endpoints such as change in Clinical Dementia Rating – Sum of Boxes (CDR-SB), enrichment strategies based on plasma ptau181, and biomarker assessments like glial fibrillary acidic protein (GFAP) to support a potential New Drug Application for neflamapimod.
Other 8-Ks document corporate governance events, including the appointment of new directors and executive officers, adoption of equity incentive plans, and stock option grants. Filings relating to the annual meeting of stockholders detail voting outcomes on director elections, auditor ratification, advisory votes on executive compensation, and approval of equity plans. Together, these documents provide a structured record of CervoMed’s governance, capital structure, and incentive arrangements.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new 8-Ks, 10-Qs, and 10-Ks as they are filed, while AI-generated highlights can point to important disclosures on clinical trial results, regulatory milestones, grant funding, and risk factors. Investors can also use the filings page to monitor how CervoMed describes its lead program, neflamapimod, and its broader strategy in age-related brain disorders over time.
CervoMed (CRVO) furnished an 8-K stating it received written feedback from the U.S. Food and Drug Administration aligning on key aspects of its proposed Phase 3 clinical trial of neflamapimod for patients with dementia with Lewy bodies. The company disclosed this via a press release furnished under Regulation FD.
Selected sections of the press release—covering the initial overview, “Phase 3 Trial Design and Regulatory Alignment,” and part of “Advancing Towards Registration”—are incorporated by reference under Other Events. The 8-K notes the press release is furnished, not filed, under the Exchange Act.
CervoMed Inc. appointed David Quigley to its Board of Directors. The Board expanded from seven to eight members, and Quigley will serve until the next annual meeting. He brings over 25 years at McKinsey, including roles leading Private Capital and Life Sciences practices.
In connection with his appointment, Quigley received a stock option for 16,200 shares at an exercise price of $7.02, vesting in 36 equal monthly installments beginning October 31, 2025, under the 2025 Equity Incentive Plan. He will also receive standard non-employee director cash and equity compensation and entered into the company’s standard director and officer indemnification agreement. Quigley will not serve on any standing committees.
CervoMed Inc. furnished a Regulation FD update, noting that an investor presentation is available on its website under “Investors – Events and Presentations.” Company representatives may use the materials periodically in meetings and conferences.
The information is being furnished, not filed, and may be updated at management’s discretion as warranted by law. The filing also lists Exhibit 104, the cover page interactive data file embedded in Inline XBRL.
CervoMed Inc. furnished an update on its lead program by sharing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies. The company issued a press release and also posted a detailed investor presentation on its website under “Investors – Events and Presentations,” which covers business, clinical studies, development plans and financial position along with the new trial results. This information is provided as a Regulation FD disclosure and is treated as “furnished,” not “filed,” and is also incorporated by reference into an other-events section of this report.
CervoMed Inc. reported a Form 4 showing that Matthew Winton, serving as Chief Commercial and Business Officer and a director-level officer, received a grant of 75,000 stock options as an inducement award tied to his employment. The options have an exercise price of $8.62 and were issued with an acquisition date of 10/06/2025. The award vests in equal monthly installments over 36 months, beginning on 10/31/2025, and the option term extends to 10/06/2035. The filing was signed on 10/07/2025.
CervoMed Inc. (CRVO) filed an initial Form 3 reporting that Matthew Winton, identified as an officer (Chief Commercial and Business), does not beneficially own any securities of the company as of the event date 10/06/2025. The filing lists Winton's business address in Boston and is signed by the reporting person. No derivative or non-derivative holdings are disclosed.
CervoMed Inc. (CRVO) received an amended Schedule 13G/A from RA Capital entities and two individuals correcting a prior filing to report warrants and resulting beneficial ownership as of June 30, 2025. The amendment discloses that RA Capital Healthcare Fund, L.P. holds warrants exercisable for up to 1,266,143 shares, but a contractual "Beneficial Ownership Blocker" limits exercise so the Fund and affiliated reporting persons may not beneficially own more than 9.99% of CervoMed's common stock. As corrected, each reporting person is shown as beneficially owning 1,026,937 shares, representing 9.99% (rounded to 9.9% on cover pages) based on 9,252,719 shares outstanding plus issuable upon exercise. The filing states the prior omission was a clerical error and disclaims group status and broader beneficial ownership except for Section 13(d) purposes.
CervoMed Inc. Schedule 13G/A filed by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah reports that each Reporting Person holds zero shares of CervoMed common stock representing 0.0% of the class as shown on the cover pages. The filers state they are not acting as a group and that the securities were not acquired to influence control of the issuer. The principal business address for the Reporting Persons is c/o RA Capital Management, L.P., Boston, MA.
CervoMed Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into Item 2.02, and the filing states that the information is being furnished under Item 2.02 rather than filed for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 (the press release) and 104 (cover page interactive data file).
CervoMed (CRVO) 10-Q, Q2-25: The neuro-focused biotech remains pre-commercial and relies on NIA grant income. Q2 grant revenue fell 46% YoY to $1.76 million as RewinD-LB funding winds down, while R&D expense rose 35% to $5.1 million and G&A climbed 30% to $3.3 million. Operating loss therefore more than doubled to $6.6 million; net loss was $6.3 million (-$0.70/sh) versus $2.3 million (-$0.27/sh) a year earlier. For the six-month period, revenue dropped 35% to $3.7 million and net loss widened to $11.2 million.
Cash & cash equivalents were $8.3 million and marketable securities $25.2 million, giving $33.5 million of liquid resources versus $38.9 million at year-end. Operating cash burn reached $10.4 million YTD, partially offset by $4.6 million raised via a May 2025 at-the-market sale of 550k shares. Management believes current funds plus remaining $2.9 million of NIA grant receivables support operations for “at least” 12 months but acknowledges the need for additional capital to advance lead asset neflamapimod beyond ongoing Phase 2 programs. Shares outstanding rose to 9.25 million.